RxDoctor Payments Data

Cynthia Saucedo, MD

Family Medicine · San Antonio, TXNPI 1114943271

Payments from drug & device makers

$1,875in general payments, 2019–2025

Across 101 payments — averaging $18.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$374
  • Amgen$309
  • Teva Pharmaceuticals USA, Inc.$174
  • Amarin Pharma, Inc.$116
  • Lilly USA, LLC$107
  • AbbVie$93
  • plus $701 from 20 others

What the payments were for

  • Food & beverage$1,875100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,875 in reported general payments places this provider in the 70th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$25,469
Medicare patients
140
Services billed
271

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide43$49,004
MounjaroTirzepatide26$38,299
JanuviaSitagliptin Phosphate17$26,891
EliquisApixaban23$26,625
Trelegy ElliptaFluticasone/Umeclidin/Vilanter16$24,681
TrulicityDulaglutide14$23,613
MyrbetriqMirabegron21$22,641
XareltoRivaroxaban15$20,671
LinzessLinaclotide15$11,118
SymbicortBudesonide/Formoterol Fumarate19$5,918
Lantus SolostarInsulin Glargine,hum.Rec.Anlog29$5,301
Levothyroxine Sodium221$2,526
Rosuvastatin Calcium211$1,927
Sumatriptan Succinate19$1,698
SynthroidLevothyroxine Sodium16$1,638

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$107$61,91340 claims
Novo NordiskOzempic$45$49,00443 claims
PfizerEliquis, Paxlovid$60$28,05438 claims
MerckJanuvia$53$26,89117 claims
GSKTrelegy Ellipta$18$24,68116 claims
Astellas Pharma US IncMyrbetriq$49$22,64121 claims
AbbVieLinzess, Synthroid, Armour Thyroid$93$13,83644 claims
AstraZenecaSymbicort$374$5,91819 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 8,760 family medicine providers in Texas.

Other family medicine in San Antonio

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →